

CLINICAL TRIAL SUMMARY DESCRIPTION

TITLE: Pirfenidone in Children and Young Adults with NF1 and progressive plexiform Neurofibromas (PNs)

OBJECTIVE OF STUDY *(please provide a description for PATIENTS interested in participating in the study):*

To find out if experimental drug can slow the growth of PNs or cause progressive PNs to shrink and study the side effects of pirfenidone

MINIMUM ELIGIBILITY REQUIREMENTS *(please include age, location and gender):* Patients between the ages of 3 and 21 years with NF1 and PNs that CANNOT be removed surgically

PARTICIPANT ACTIVITIES *(office visits, tests, take medications, etc):* Patients will take the drug 3 times a day for 28 days, and keep a daily log during this 28-day period. Patients must also agree to a medical screening including a MRI of PNs, and where necessary, a biopsy.

CONTACT INFORMATION: **COORDINATOR / CHAIR** *(please circle one)*

NAME/TITLE: Dr. Roger Packer

AFFILIATION: National Cancer Institute

MAILING ADDRESS: Patient Recruitment and Public Liaison Office
National Cancer Institute
9000 Rockville Pike
Bethesda, MD 20892 USA

PHONE: 202.884.2120

Email ADDRESS: rpacker@cnmc.org

WEBSITE *(for complete info):* <http://clinicaltrials.gov/show/NCT00076102>